You are here

Valeant goes on defensive against investor critics

It is publicly revealing for the first time the benefits that it gets from some price increases; says it has not been as dependent on drug price increases as analysts' reports claim

San Francisco

AMID an intensifying debate over drug price increases that has brought its business practices to the forefront, Valeant Pharmaceuticals International Inc fired back at critics in the investment community, publicly revealing the benefits that it gets from some price hikes for